Drug Approval | March 01, 2024
Biocon Biologics secures US market entry date for Bmab 1200
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
Innovent will supply sintilimab for the collaborated clinical trial
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
10+ emerging markets, Japan & ANZ transition in final phase
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Subscribe To Our Newsletter & Stay Updated
